Diligence memo · auto-generated · as of July 2, 2026

Rose Pharmaceuticals, LLC.

Rose Pharmaceuticals, LLC. looks under-valued against its niche peers and is active on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

Rose Pharmaceuticals, LLC. operates in Pharmaceuticals, based in WEST PALM BEACH.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Rose Pharmaceuticals, LLC. has raised $8.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $8.0M on —.

Valuation (modeled)modeled

Provath models Rose Pharmaceuticals, LLC. at approximately $17M (range $9.2M–$23M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.13× the median modeled value of Series A Pharmaceuticals companies (418 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

No dated round to assess.

Comparablesmixed

Capital scale ranks ahead of 50% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 25% of those peers.

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.